Cancer Network spoke with Dr. Karyn Goodman about the importance of developing a systematic therapy regimen for the treatment of esophagogastric cancer.
Pembrolizumab showed promise in the second-line setting for patients with metastatic esophageal cancer and high PD-L1 expression.
A large pooled analysis of individuals with advanced esophageal cancer showed men and women have different side effects to chemotherapy.
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC.
As part of our coverage of the 2018 GI Cancers Symposium, we discussed the role of locoregional therapies for patients with metastatic esophageal and gastric cancers.
Patients assigned to robot-assisted minimally invasive thoraco-laparoscopic esophagectomy had fewer overall, surgery-related, and cardiopulmonary complications compared with open transthoracic esophagectomy, according to the results of the ROBOT trial.
First-line ramucirumab in combination with chemotherapy significantly improved progression-free survival in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the RAINFALL trial.
Treatment with the anti–PD-1 antibody pembrolizumab resulted in durable antitumor activity with manageable side effects in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma, according to phase IB results of the KEYNOTE-028 study.
Treatment with adjuvant chemotherapy improved the overall survival of locally advanced gastroesophageal adenocarcinoma in patients treated with preoperative chemoradiotherapy and resection, according to the results of an analysis of the National Cancer Database.
The use of hybrid minimally invasive esophagectomy reduced postoperative morbidity in patients with esophageal cancers, according to the results of the MIRO trial.